Regulus Therapeutics, a biopharmaceutical company focused on developing drugs that target microRNA, announced terms for its IPO on Friday. The San Diego, CA-based company plans to raise $50 million by offering 4.5 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Regulus Therapeutics would command a market value of $239 million. Regulus Therapeutics, which was founded in 2007 and booked $14 million in sales for the 12 months ended June 30, 2012, plans to list on the NASDAQ under the symbol RGLS. Lazard Capital Markets, Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal.
